Ervex 150 Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

The most common adverse effects associated with erlotinib hydrochloride are rash and diarrhoea. Moderate or severe diarrhoea should be treated with an appropriate antidiarrhoeal such as loperamide; dose reduction may be needed. In more severe or persistent cases leading to dehydration, therapy should be stopped temporarily. Other common adverse effects include other gastrointestinal disturbances, gastrointestinal bleeding, fatigue, alopecia, stomatitis, pruritus, dry skin, paronychia, conjunctivitis, keratoconjunctivitis sicca, epistaxis, and abdominal pain. Alterations in liver function tests have occurred. Rare cases of hepatic failure, including fatalities, have been reported. Interstitial lung disease has also been reported; fatalities have occurred. Erlotinib treatment should be interrupted if unexplained pulmonary symptoms occur, such as dyspnoea, cough, and fever.

View ADR Reporting Link

erlotinib

Manufacturer:

Vexxa Lifesciences

Distributor:

VE Pharma